Skip to content

Roivant Sciences ROIV Free cash flow

Free cash flow at other companies

Amgen logo
AmgenAMGN
$1.48B+50.7%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
-$95.07M+14.2%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$757M-55.3%
AbbVie logo
AbbVieABBV
$3.56B+155%
Regenxbio logo
RegenxbioRGNX
-$77.42M-337%
Moderna logo
ModernaMRNA

Other financials

Income statement

See full
Revenue$2.5M-66.7%
Operating income-$339.2M-23.6%
Net income-$265.9M-257%
EPS (diluted)-$0.38-265%

Balance sheet

See full
Cash & equivalents$1.4B+1,411%
Total debt$107.4M+7.3%
Total equity$4.5B-3.4%
Total assets$5.7B+5.0%

Cash flow

See full
Operating cash flow-$163.8M+5.1%
CapEx$1.3M+55.5%

Valuation

See full
Market cap$25.45B+220%
Enterprise value$24.14B+204%
P/S3,081.7×+2,740×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp
FCF margin-9,183.5%-17,093pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio18.4×-15.1×

Where this comes from

Calculated from Roivant Sciences’s reported figures.

The official record: Roivant Sciences’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Roivant Sciences's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Roivant Sciences's free cash flow?
Roivant Sciences (ROIV) reported free cash flow of -$165.08M in Q1 2026.
How has Roivant Sciences's free cash flow changed year-over-year?
Roivant Sciences's free cash flow increased by 4.8% year-over-year, from -$173.38M to -$165.08M.
What is the long-term trend for Roivant Sciences's free cash flow?
Over 4 years (2021 to 2025), Roivant Sciences's free cash flow has grown at a 2.2% compound annual growth rate (CAGR), from -$695.17M to -$758.56M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.